Approval · Notice of Compliance 13798 · 2012
TEVA-VALACYCLOVIR: Notice of Compliance 13798
Issued November 1, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13798
- Date
- November 1, 2012
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product name change
- Therapeutic class
- Antiviral agent
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-VALACYCLOVIR | 02357534 | Marketed |
| TEVA-VALACYCLOVIR | 02357542 | Cancelled Pre Market |
Medicinal ingredients
- VALACYCLOVIR HYDROCHLORIDE 500 MG per TAB
- VALACYCLOVIR HYDROCHLORIDE 1,000 MG per TAB